InfuSystem Holdings, Inc. - Q1 2010 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2010. InfuSystem Holdings, Inc. is a provider of ambulatory infusion pump management services, primarily for oncology patients receiving chemotherapy. The company rents electronic pumps and supplies to over 1,300 oncology practices in the United States. As of May 4, 2010, there were 19,764,635 shares of common stock outstanding.
Key Financial Metrics
| Metric | Q1 2010 | Q1 2009 |
|---|---|---|
| Net Revenues | $10,934,000 | $9,227,000 |
| Operating Income | $1,492,000 | $1,261,000 |
| Net Loss | $(12,000) | $(2,507,000) |
| Cash from Operations | $1,463,000 | $1,269,000 |
| Cash and Equivalents (End of Period) | $7,718,000 | $11,358,000 |
| Total Debt (Current + Long-term) | $23,760,000 | N/A |
| Working Capital (excl. derivatives) | $6,522,000 | N/A |
Note: Debt figures include a term loan with Kimberly-Clark (formerly I-Flow) and capital lease obligations.
Material Changes vs. Prior Period
- Revenue Growth: Net revenues increased 19% year-over-year, driven by new customer facilities and deeper penetration in existing accounts.
- Profitability Improvement: The company reported a net loss of only $12,000, a significant improvement from the $2.5 million net loss in Q1 2009. This was largely due to a reduction in "Loss on derivatives."
- Derivative Liability Reduction: The loss on derivatives decreased from $2.64 million in Q1 2009 to $389,000 in Q1 2010. This improvement followed a warrant exchange offer in March 2010, which reduced the number of outstanding warrants classified as liabilities from 35.1 million to 9.5 million.
- Cost Increases: Cost of revenues rose 33% to $2.81 million, primarily due to increased pump depreciation and repair costs associated with revenue growth. The provision for doubtful accounts increased to $1.39 million (13% of revenue) from $969,000 (11% of revenue).
Outlook, Risks, and Contingencies
- Debt Covenants: The company is subject to strict covenants under its term loan with Kimberly-Clark, including fixed charge coverage, leverage ratios, and minimum EBITDA requirements. Management believes it is in compliance as of March 31, 2010.
- Earn-Out Obligation: There is a potential earn-out payment of up to $12 million to Kimberly-Clark in 2011 if the company achieves a 40% consolidated net revenue CAGR over a three-year period. As of Dec 31, 2009, the two-year CAGR was 11%.
- Subsequent Events: On April 8, 2010, the company made a required excess cash flow principal prepayment of $1.25 million on its term loan. Additionally, significant share awards were granted to the CEO and Directors in April 2010.
- Key Risks: The company relies heavily on third-party payors (Medicare is ~31% of gross billings). Changes in reimbursement rates or collection estimates could materially impact results. The company also faces market risk regarding the fair value of remaining warrant liabilities.
Investor Verification Checklist
- Warrant Liability Volatility: Verify the current fair value of the remaining 8.3 million publicly held warrants, as fluctuations directly impact net income via "Loss on derivatives."
- Debt Covenant Compliance: Confirm continued compliance with the Kimberly-Clark term loan covenants, specifically the fixed charge coverage and minimum EBITDA requirements.
- Reimbursement Trends: Monitor the "Provision for doubtful accounts" as a percentage of revenue, which rose to 13%, indicating potential collection headwinds with third-party payors or patients.
- Earn-Out Feasibility: Assess the likelihood of achieving the 40% CAGR target required to trigger the $12 million earn-out payment in 2011.
- Liquidity Position: Review cash burn relative to the $7.7 million cash balance and the upcoming $1.25 million debt prepayment obligation.